January 2020 – Aggressive NHL is among the most common cancers in SSA where CHOP is the standard treatment and outcomes are poor. We treated patients with a modified EPOCH regimen with moderate outcomes. Results indicate that this regimen was feasible and effective in a small cohort and suggest EPOCH with setting-appropriate modifications may be … Read more

November 2019 – Although plasma EBV DNA measurement has established prognostic utility in EBV‐driven lymphomas, findings from this study suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive patients with convincingly EBV‐negative DLBCL.

October 2019 – Increasing access to conventional cancer treatment in low-income countries is an important public health initiative to address the global burden of cancer. Our findings indicate that cancer patients in our cohort rely on a pragmatic and experience-based treatment selection process and provide insights to the various factors that influence T&CM use among cancer … Read more

July 2019 – Cost analysis of treating diffuse large B-cell lymphoma (DLBCL) in Malawi indicates that per-patient cost of first-line treatment of DLBCL in Malawi is low relative to high-income countries, suggesting that investments in fixed-duration, curative-intent DLBCL treatment may be attractive in sub-Saharan Africa.

February 2019 – Although Burkitt lymphoma (BL) is common in sub-Saharan Africa (SSA) and highly curable in high-income countries, there are few prospective nonpediatric BL studies from SSA and no regional standard of care. This study represents one of the best characterized prospective cohorts of nonpediatric BL in SSA.

December 2018- Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa are poorly described. We report mature data from one of the first prospective SSA cohorts and propose a setting-appropriate prognostic model.

November 2018-  Despite high burden of Kaposi sarcoma and HIV, multicentric Castleman disease is rarely reported in SSA. To supplement previous reports on MCD cases in Malawi, we describe a larger cohort of MCD patients with longer follow-up.

September 2018- Although HIV and HHV8 are highly prevalent in SSA, there are scarce reports of primary effusion lymphoma (PEL) from the region, likely reflecting underdiagnosis. This article describes the two recently confirmed cases of extracavitary PEL in Malawi.  

July 2018- Although highly effective, high-intensity cytotoxic treatments for Burkitt lymphoma are available in resource-rich settings, these therapies are usually not feasible in SSA, and lower-intensity continuous infusion approaches are impractical. We review current treatment approaches in SSA and discuss options for risk stratification and individualize therapy.

June 2018- Despite high prevalence of HIV in SSA, descriptions of Plasmablastic lymphoma (PBL) are scare.  In one of the first clinical descriptions of PBL, we report on characteristics, treatment, and outcomes of 12 pathologically confirmed PBL cases in Lilongwe.